Good news from New York as Pfizer and the German pharmaceutical company BioNTech have started human trials on a COVID-19 vaccine on Monday. If the trial is successful, the vaccine could be ready as early as September for emergency use. That would be the same timeline announced by Oxford University for the COVID-19 vaccine that they are currently testing.
The firms are developing this vaccine that his based on a genetic material known as RNA messenger whose function will help the immune system to produce antibodies to fight off an infection.
This technique is extremely effective also because comparing it to the other vaccines is faster to produce and also more stable.
The Human Trial
Pfizer and BioNTech have already injected the new vaccine to the first volunteers’ las month in Germany. In the US, the companies will execute the trial on 360 healthy volunteers as a first step to then adding 8,000 volunteers in the second stage.
The volunteers will be divided into groups according to the 4 variations of the vaccine. Of course, the doctors will closely monitor the volunteers and possible side effects.
The tests will be conducted in parallel so as to get enough data to receive the approval from the FDA for emergency use and have the first million doses already available in September.
Dr. Mikael Dolsten, Pfizer’s chief scientific officer, commented: “We need to think differently, we need to think faster. If we get hit with a second wave of coronavirus infections in October at the same time as the flu, things will be much worse than what we’ve already experienced.”
SHARE in FB to help CHARITIES See how